RLAY$17.813.07%0.53
Relay Therapeutics Inc (RLAY)
Date: 2026-11-03 16:00O: 17.52H: 18.01L: 17.28C: 17.81Vol: 1.197M
Relay Therapeutics Inc stock is traded at $17.81, with a volume of 1,201,372. It is up +3.07% in the last 24 hours and down -6.07% over the past month. Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Previous Close:
$17.28
Open:
$17.52
24h Volume:
1,201,372
Relative Volume:
0.54
Market Cap:
$3.90B
Revenue:
$10.68M
Net Income/Loss:
-$272.71M
P/E Ratio:
-
EPS:
-$1.57
Net Cash Flow:
-$213.38M
1W Performance:
-5.47%
1M Performance:
-6.07%
6M Performance:
+40.02%
1Y Performance:
+156.63%
1-Day Range:
$17.28$18.01
1-Week Range:
$17.24$20.20
52-Week Range:
$5.95$21.27
Relay Therapeutics Inc Stock (RLAY) Company Profile
Name
Relay Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-370-8837Address
60 HAMPSHIRE STREET, CAMBRIDGE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Relay Therapeutics Inc Stock (RLAY) Financials Data
Relay Therapeutics Inc Stock (RLAY) Insider Trading
- Bergstrom Donald AOct 28 '26President, R&D
- Transaction
- Sale
- Cost
- $18.62
- #Shares
- 2,252
- Value ($)
- 41,932
- #Shares Total
- 396,878
- Rahmer PeterOct 28 '26See remarks
- Transaction
- Sale
- Cost
- $18.62
- #Shares
- 753
- Value ($)
- 14,021
- #Shares Total
- 222,904
- Catinazzo ThomasOct 28 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $18.62
- #Shares
- 1,469
- Value ($)
- 27,353
- #Shares Total
- 103,665
- Patel SanjivOct 07 '26President and CEO
- Transaction
- Sale
- Cost
- $18.10
- #Shares
- 48,199
- Value ($)
- 872,402
- #Shares Total
- 471,301
- SANJIV PATELOct 07 '26Director
- Transaction
- Proposed Sale
- Cost
- $18.74
- #Shares
- 96,401
- Value ($)
- 1,806,555
- #Shares Total
- 0
- THOMAS CATINAZZOOct 06 '26Officer
- Transaction
- Proposed Sale
- Cost
- $19.39
- #Shares
- 93,153
- Value ($)
- 1,806,237
- #Shares Total
- 0
- Catinazzo ThomasOct 06 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $18.59
- #Shares
- 17,717
- Value ($)
- 329,322
- #Shares Total
- 105,134
- Bergstrom Donald ASep 08 '26President, R&D
- Transaction
- Sale
- Cost
- $18.97
- #Shares
- 8,530
- Value ($)
- 161,814
- #Shares Total
- 399,130
- Patel SanjivSep 08 '26President and CEO
- Transaction
- Sale
- Cost
- $18.94
- #Shares
- 48,199
- Value ($)
- 912,889
- #Shares Total
- 519,500
- Catinazzo ThomasSep 08 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $18.94
- #Shares
- 17,717
- Value ($)
- 335,560
- #Shares Total
- 122,851
